“While ACRO is ever-changing and evolving, our focus has always remained the same: ensuring the delivery of safe, efficient, and effective clinical trials for the benefit of patients around the world.”
In ACRO’s 2024 outlook, Peyton Howell, Chief Operating and Growth Officer at Parexel and chair of ACRO’s board of directors, speaks to how ACRO’s members continue to come together to meet the needs of the moment and make trials better for patients.
Whether it be through meeting the new challenges and opportunities associated with the use of AI/ML in drug development or through the continued sharing of experiences and information with the goal of ensuring the safety of trial participants and researchers in areas of conflict around the world, ACRO members remain united by our shared goals of continuing to improve drug development.
Watch the 2024 Outlook:
The DIA 2024 Global Annual Meeting invites industry, regulators, governments, academics, innovators, and patients to network, problem-solve, and discuss global and local challenges facing the life sciences community. Hosted in San Diego, DIA 2024 will amplify different perspectives while highlighting expertise across the globe to reimagine current processes that better enhance health and well-being. Register now!